Page last updated: 2024-08-21

dronabinol and Sclerosis, Systemic

dronabinol has been researched along with Sclerosis, Systemic in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (33.33)	24.3611
2020's	2 (66.67)	2.80

Authors

Authors	Studies
Bloom, BJ; Chung, L; Constantine, S; de Vries-Bouwstra, J; Denton, CP; Dgetluck, N; Dinh, Q; Distler, O; Finzel, S; Frech, TM; Furst, DE; Gordon, J; Hsu, V; Hummers, L; Jankowski, T; Jun, JB; Kafaja, S; Khanna, D; Kuwana, M; Lee, EB; Leszcyzński, P; Levy, Y; Litinsky, I; Matucci-Cerinic, M; Mayes, M; Sandorfi, N; Simms, RW; Spiera, R; Steen, V; Stevens, W; White, B	1
Chung, L; Constantine, S; Dgetluck, N; Domsic, R; Frech, TM; Furst, DE; Gordon, J; Hsu, V; Hummers, L; Lafyatis, R; Lee, E; Martyanov, V; Mayes, M; Simms, R; Spiera, R; White, B; Whitfield, ML; Wood, T	1
Akhmetshina, A; Baldi, C; Balistreri, E; Capecchi, PL; Distler, JH; Galeazzi, M; Gianchecchi, E; Gonzalez, EG; Lazzerini, PE; Lorenzini, S; Lucattelli, M; Montilli, C; Palumbo, K; Pasini, FL; Selvi, E	1

Trials

2 trial(s) available for dronabinol and Sclerosis, Systemic

Article	Year
Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis. Arthritis & rheumatology (Hoboken, N.J.), 2023, Volume: 75, Issue:9 Topics: Cannabinoid Receptor Agonists; Dronabinol; Humans; Scleroderma, Diffuse; Scleroderma, Systemic; Severity of Illness Index; Skin; Treatment Outcome	2023
Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo-Controlled Trial in Adults With Systemic Sclerosis. Arthritis & rheumatology (Hoboken, N.J.), 2020, Volume: 72, Issue:8 Topics: Adolescent; Adult; Aged; Cannabinoid Receptor Agonists; Double-Blind Method; Dronabinol; Drugs, Investigational; Female; Humans; Male; Middle Aged; Receptor, Cannabinoid, CB2; Scleroderma, Systemic; Severity of Illness Index; Skin; Synthetic Drugs; Treatment Outcome; Young Adult	2020

Article

Year

Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis.

Arthritis & rheumatology (Hoboken, N.J.), 2023, Volume: 75, Issue:9

Topics: Cannabinoid Receptor Agonists; Dronabinol; Humans; Scleroderma, Diffuse; Scleroderma, Systemic; Severity of Illness Index; Skin; Treatment Outcome

2023

Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo-Controlled Trial in Adults With Systemic Sclerosis.

Arthritis & rheumatology (Hoboken, N.J.), 2020, Volume: 72, Issue:8

Topics: Adolescent; Adult; Aged; Cannabinoid Receptor Agonists; Double-Blind Method; Dronabinol; Drugs, Investigational; Female; Humans; Male; Middle Aged; Receptor, Cannabinoid, CB2; Scleroderma, Systemic; Severity of Illness Index; Skin; Synthetic Drugs; Treatment Outcome; Young Adult

2020

Other Studies

1 other study(ies) available for dronabinol and Sclerosis, Systemic

Article	Year
Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis. Annals of the rheumatic diseases, 2012, Volume: 71, Issue:9 Topics: Adult; Aged; Animals; Cannabinoids; Collagen; Disease Models, Animal; Dronabinol; Female; Fibroblasts; Fibrosis; Humans; Male; Mice; Middle Aged; Scleroderma, Systemic	2012